Navigation Links
Portable device quickly detects early Alzheimer's

ATLANTA (January 16, 2008) The latest medications can delay the onset of Alzheimer's disease, but none are able to reverse its devastating effects. This limitation often makes early detection the key to Alzheimers patients maintaining a good quality of life for as long as possible.

Now, a new device developed by the Georgia Institute of Technology and Emory University may allow patients to take a brief, inexpensive test that could be administered as part of a routine yearly checkup at a doctors office to detect mild cognitive impairment (MCI) often the earliest stage of Alzheimers. The device is expected to be commercialized later this year.

Current assessment tests capable of detecting early Alzheimers typically are taken with a pen and paper or at a computer terminal and last about an hour and a half. They must be given by a trained technician in a quiet environment, because any distractions can influence the patients score and reduce the tests effectiveness. Because of their length and expense, the tests are not used as regular screening tools and typically are given only after there is obvious cognitive impairment such as forgetfulness or unsafe behavior.

Families usually wait until their mom or dad does something somewhat dangerous, like forgetting to take their medications or getting lost, before bringing them in for testing. At that point, the patient has already lost a significant portion of their cognitive function, said David Wright, MD, who helped develop the device. Wright is assistant professor of emergency medicine at Emory University School of Medicine and co-director of the Emory Emergency Medicine Research Center. With this device, we might be able to pick up impairment well before those serious symptoms occur and start patients on medications that could delay those symptoms.

The Georgia Tech and Emory device, called DETECT, gives individuals a roughly ten-minute test designed to gauge reaction time and memory functions that, when impaired, are associated with the earliest stages of Alzheimer's disease. The test is a specially modified, shortened version of the traditional pen and paper test and could be given repeatedly by doctors to evaluate any changes in cognitive functions.

We really envision this to be part of the normal preventative care a patient receives from a general practitioner, said Michelle LaPlaca, Ph.D., one of the creators of the device and an associate professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University. It would be part of a regular preventative medicine exam much like a PSA test or EKG (electrocardiogram), serving as a cognitive impairment vital sign of sorts.

The portable test runs patients through a battery of visual and auditory stimuli such as pictures and words that assess cognitive abilities relative to age, gauging reaction time and memory capabilities. Its software can track cognitive capabilities and decline year to year during annual appointments. And because the device blocks outside sound and light from the patients environment, it can be administered in virtually any setting, providing more consistent results.

Preliminary analysis of the first 100 patients of a 400-person clinical study being conducted at Emory's Wesley Woods Center has shown that the 10-minute DETECT test has similar accuracy to the 90-minute Gold Standard pen and paper test.

With millions of baby boomers easing into late adulthood, the number of patients with Alzheimers is expected to skyrocket over the next few decades. More than 24 million people worldwide are currently thought to have Alzheimers disease and by 2040, an estimated 81 million people worldwide are expected to develop the disease.

To give these millions of potential Alzheimers sufferers a chance to slow the diseases advance before serious symptoms set in, doctors need an inexpensive and easy-to- administer test to detect and track the cognitive decline associated with the early stages of the disease.

The DETECT device is designed to be administered while a patient is still healthy, tracking any abnormal decreases in the patients cognitive performance over time. If a patients performance declines outside the normal range, the patient would then undergo additional testing and care from a neurologist, neuropsychologist or other specialist.

The DETECT system includes an LCD display in a visor with an onboard dedicated computer, noise reduction headphones and an input device (controller). The display projects the visual aspect of the test, the headphones provide the verbal instructions and the controller records the wearers response.

DETECTs creators have formed a company, called Zenda Technologies (, to commercialize the device for MCI, as well as other conditions. Georgia Tech and Emory researchers are exploring other types of cognitive impairment such as Attention Deficit/Hyperactivity Disorder (ADHD) that could be picked up by DETECT. A version of the system designed to detect mild concussions on the sidelines of a football game, during other high-impact sports or on a battlefield is still being tested.


Contact: Megan McRainey
Georgia Institute of Technology

Related biology news :

1. Portable electricity, life-like prosthetics on the way
2. Smiths Detection to launch a portable diagnostic system for foot-and-mouth disease and avian flu
3. Silex Introduces Worlds First Wireless USB Device Server With Streaming Video and Audio Data Transfer
4. Stanford researchers publish review of US medical device regulation
5. Device prevents potential errors in childrens medications
6. Better protection for biomedial devices could result from Rutgers-Camden research
7. EMD Serono launches easypod, new electronic growth hormone injection device
8. Atmospheric measuring device for understanding smog formation
9. MIT aids creation of neural prosthetic devices
10. IGERT fellows to design biodevices using flexible electronics
11. Researchers developing device to predict proper light exposure for human health
Post Your Comments:
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
(Date:4/5/2017)... Allen Institute for Cell Science today announces the launch ... dynamic digital window into the human cell. The website ... deep learning to create predictive models of cell organization, ... suite of powerful tools. The Allen Cell Explorer will ... resources created and shared by the Allen Institute for ...
(Date:4/5/2017)... 4, 2017 KEY FINDINGS The ... at a CAGR of 25.76% during the forecast period ... primary factor for the growth of the stem cell ... MARKET INSIGHTS The global stem cell market ... and geography. The stem cell market of the product ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity of ... performing systematic gain-of-function studies. , This complement to loss-of-function studies, such as ...
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... (ADC) therapeutics, today confirmed licensing rights that give it exclusive global access ... developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, an ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... optimization firm for the life sciences and healthcare industries, announces a presentation by ... Francisco. , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present ...
Breaking Biology Technology: